Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 15/20 | 0.46 |
| ▸ | CDK2 | P24941 | 15/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 15/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045185 | 0.93 | CCNA2 (0.48) | BTKCCNA2CDK2CCNA1 | |
| SCHEMBL9984813 | 0.91 | BTK (0.45) | BTKCCNA2CDK2CCNA1 | |
| SCHEMBL2489481 | 0.91 | BTK (0.44) | BTKCCNA2CDK2CCNA1 | |
| SCHEMBL9984448 | 0.87 | BTK (0.42) | BTKCCNA2CDK2CCNA1 | |
| SCHEMBL2464012 | 0.83 | BTK (0.52) | BTKCCNA2CDK2CCNA1 | |
| SCHEMBL9984872 | 0.80 | BTK (0.69) | BTK | |
| SCHEMBL2492576 | 0.79 | BTK (0.67) | BTKCCNA2CDK2CCNA1 | |
| SCHEMBL2459246 | 0.79 | BTK (0.43) | BTK | |
| SCHEMBL19981928 | 0.79 | CDK2 (0.41) | BTKCCNA2CDK2CCNA1 | |
| SCHEMBL12045182 | 0.79 | BTK (0.48) | BTKCCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598174-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC. (US) | 2013-12-03 | — | — | US | claimed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | claimed |
| EP-2365970-B1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-8598174-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2365970-A1 | Pyridazinones and their use as btk inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | BTK 1/4885CCNA2 1346/4885CDK2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.